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Abstract
Background: Although Candida species are commensal microorganisms, they can cause many invasive fungal
infections. In addition, antifungal resistance can contribute to failure of treatment.
The purpose of this study was to evaluate the antifungal activity of inhibitors of Δ24(25)-sterol methyltransferase
(24-SMTI), 20-piperidin-2-yl-5α-pregnan-3β-20(R)-diol (AZA), and 24(R,S),25-epiminolanosterol (EIL), against
clinical isolates of Candida spp., analysing the ultrastructural changes.
Results: AZA and EIL were found to be potent growth inhibitors of Candida spp. isolates. The median MIC50 was
0.5 μg.ml-1 for AZA and 2 μg.ml-1 for EIL, and the MIC90 was 2 μg.ml-1 for both compounds. All strains used in this
study were susceptible to amphotericin B; however, some isolates were fluconazole- and itraconazole-resistant.
Most of the azole-resistant isolates were Candida non-albicans (CNA) species, but several of them, such as C.
guilliermondii, C. zeylanoides, and C. lipolytica, were susceptible to 24-SMTI, indicating a lack of cross-resistance.
Reference strain C. krusei (ATCC 6258, FLC-resistant) was consistently susceptible to AZA, although not to EIL.
The fungicidal activity of 24-SMTI was particularly high against CNA isolates. Treatment with sub-inhibitory
concentrations of AZA and EIL induced several ultrastructural alterations, including changes in the cell-wall shape
and thickness, a pronounced disconnection between the cell wall and cytoplasm with an electron-lucent zone
between them, mitochondrial swelling, and the presence of electron-dense vacuoles. Fluorescence microscopy
analyses indicated an accumulation of lipid bodies and alterations in the cell cycle of the yeasts. The selectivity of
24-SMTI for fungal cells versus mammalian cells was assessed by the sulforhodamine B viability assay.
Conclusion: Taken together, these results suggest that inhibition of 24-SMT may be a novel approach to control
Candida spp. infections, including those caused by azole-resistant strains.
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Background
Candida species are commensal microorganisms of verte-
brate hosts that can cause infections ranging from non-
life-threatening to invasive illnesses. Although candidae-
mia is the most common manifestation of invasive candi-
diasis, extensive visceral invasion with Candida can occur
in all organs. The eyes, brain, liver, spleen, and kidneys are
the most commonly affected [1]. Candidiasis is the fourth
most common cause of nosocomial bloodstream infec-
tions in Brazil and the U.S.A., with a mortality rate of
approximately 40% [1,2]. A progressive increase in the
number and severity of candidiasis over the past two dec-
ades has been observed worldwide, especially in immuno-
compromised patients and also in patients hospitalised
with serious underlying diseases, during immunosuppres-
sive therapy, or parenteral nutrition, as well as among
patients exposed to invasive medical procedures. Yeasts of
Candida albicans are the most frequently implicated in
cases of invasive candidiasis infections. However, nowa-
days Candida non-albicans (CNA) species such as Candida
glabrata,  Candida krusei, and Candida parapsilosis have
increased in importance and number among fungal infec-
tions [1].
Currently, the mainstay of chemotherapy employed for
the treatment of fungal infections comprises drugs that
affect the function or biosynthesis of membrane sterols
[3]. The polyenes (such as amphotericin B) were the first
antifungal class used to treat invasive fungal infections.
The primary mechanism of amphotericin B is its binding
to the signature 24-alkyl sterols present in fungal cell
membranes, leading to a perturbation of the membrane
selective permeability and, consequently, loss of the cellu-
lar content. Despite the specific fungicidal effect of pol-
yenes, they display significant toxicity to mammalian cells
[4]. Another important antifungal class comprises the
azoles, such as ketoconazole, fluconazole (FLC), itracona-
zole (ITC), posaconazole, and voriconazole, which are the
compounds most frequently used today, and whose spe-
cific target is the cytochrome P-450-dependent C14α-
demethylase, a key enzyme of the ergosterol biosynthesis
pathway [4]. Although azoles are one of the main classes
of drugs used in the treatment of fungal infections, these
drugs present several problems such as their fungistatic
rather than fungicidal activity, variable drug bioavailabil-
ity, lack of intravenous preparations, large number of
drug-drug interactions, development of resistance, and
potential cross-resistance between different azoles [5].
During the last two decades, some studies have described
a new class of antifungals called azasterols, which are
inhibitors of the Δ24(25)-sterol methyltransferase (24-
SMT), another key enzyme of the ergosterol biosynthesis
pathway, which is absent in the mammalian host cells [6-
8]. This enzyme catalyses the S-adenosylmethionine-
mediated incorporation of methyl groups at position 24
in sterols, which is an essential step for the biosynthesis of
fungal sterols [6,8]. 20-piperidin-2-yl-5α-pregnan-3β-
20(R)-diol (AZA) and 24(R,S),25-epiminolanosterol
(EIL) are steroid compounds with a nitrogen atom in the
side chain (azasterols, Fig. 1), and are known inhibitors of
24-SMT in fungi [9], Trypanosoma cruzi [10], and Leishma-
nia amazonensis [11,12]. Antifungal activities of these
inhibitors were also described against Pneumocytis carinii
[13] and Paracoccidioides brasiliensis [14].
The purpose of the present study was to (i) examine the
susceptibilities of a collection of 70 yeasts of the genus
Candida  to AZA and EIL; (ii) determine the fungicidal
activities of these compounds; and (iii) detect the main
morphology and ultrastructural alterations of the yeasts
after drug treatment.
Results
Antifungal susceptibility of Candida isolates
The MICs obtained for the ATCC strains to standard drugs
(AMB, FLC, and ITC) and to the experimental compounds
(AZA and EIL) are listed in Table 1. Interestingly, C. krusei
(ATCC 6258, FLC-resistant) has AZA MIC50 of 1 μg.ml-1
and MIC90 of 2 μg.ml-1. On the other hand, EIL did not
inhibit the growth of the FLC- and ITC-resistant strains.
All clinical isolates were susceptible to AMB, with the
median MIC50 values ranging from 0.015 to 0.25 μg.ml-1
and the MIC90 from 0.12 to 0.5 μg.ml-1 (Table 2). How-
ever, three isolates (two C. tropicalis and one C. guilher-
mondii) showed MIC90  values higher than 1 μg.ml-1.
Susceptibility to FLC was observed in 92% of the isolates,
although 26% showed a trailing effect. Clear resistance to
FLC was detected in three isolates (two C. tropicalis and
one C. krusei). 45% of the strains showed MIC50 of 0.25–
0.50 μg.ml-1 and 37% showed MIC90 of 0.50–1 μg.ml-1.
On the other hand, 75% of the isolates were susceptible to
ITC, and 16% showed a trailing effect. Resistance to ITC
was detected in 6 isolates (3 C. tropicalis, 1 C. albicans, 1 C.
glabrata, and 1 C. krusei). Most of the isolates had MIC50
and MIC90 for ITC lower than 0.03 μg.ml-1 (62%, and
Molecular structures of 20-piperidin-2-yl-5α-pregnan-3β,20- diol (22,26-azasterol, AZA) and 24 (R,S),25-epiminolanos- terol (EIL) Figure 1
Molecular structures of 20-piperidin-2-yl-5α-pregnan-
3β,20-diol (22,26-azasterol, AZA) and 24 (R,S),25-epi-
minolanosterol (EIL).BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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41%, respectively). Only C. krusei isolates were less sus-
ceptible to all standard drugs, showing a MIC90 of 0.5
μg.ml-1 for AMB, > 128 μg.ml-1 for FLC, and 2 μg.ml-1 for
ITC (Table 2).
When the MIC values for 24-SMTI (AZA and EIL) were
analysed, we observed important antifungal activity for
almost all Candida spp. isolates (Table 3). For AZA, MIC50
and MIC90 values lower than 2 μg.ml-1 were observed in
86% and 52% of the isolates, respectively. For EIL, MIC50
and MIC90 values lower than 2 μg.ml-1 were observed in
92% and 63% of the isolates, respectively. C. zeylanoides
and C. lipolytica (a rarely observed CNA) showed MIC50–90
values of ≤ 0.03 μg.ml-1 for both inhibitors, whilst C. kru-
sei was resistant to EIL, with MIC50–90 values of 8 μg.ml-1
(Table 3). However, both C. krusei and C. lipolytica were
resistant to AZA (MIC50–90 ≥ 16 μg.ml-1) (Table 3). Finally,
C. guilliermondii isolates, FLC- and ITC-resistant, were sus-
ceptible to AZA, with MIC50–90 values of 0.06 – 0.25
μg.ml-1.
Correlations between MIC values
Positive correlations of the MIC50 values were observed
between AZA and AMB (r = 0.47), AZA and EIL (r = 0.46),
and FLC and ITC (r = 0.79). In addition, positive correla-
tions were observed between the MIC90 values of the FLC
and ITC (r = 0.71). On the other hand, no significant cor-
relations were observed between the MIC values for azoles
and 24-SMTI. Some clinical isolates with a trailing effect
for FLC (n = 17) and ITC (n = 11) also showed residual
growth at higher concentrations of AZA (16 μg.ml-1) of
58% (10/17) and 54% (6/11) of the isolates, respectively.
Residual growth was not observed in the isolates after
treatment with EIL.
Minimum fungicidal concentration (MFC) of AZA and EIL
The MFCs obtained for half of our isolates were higher
than 16 μg.ml-1, revealing a predominant fungistatic activ-
ity of the SMTI. Interestingly, 4 CNA isolates (C. glabrata,
C. lusitaneae, C. zeylanoides, and C. rugosa) showed MFCs
lower than 4 μg.ml-1, indicating a remarkable fungicidal
activity, especially for AZA (Table 4). On the other hand,
AZA killed a negligible number of the C. albicans isolates
at concentrations lower than 16 μg.ml-1.
Ultrastructural effects
The general morphology of untreated C. albicans was
observed using scanning (Figure 2a) and transmission
(Figure 2b–c) electron microscopy. The shape of C. albi-
cans varies from spherical (4.90 ± 0.49 μm diameter) to
oval cells when viewed by scanning electron microscopy
(Figure 2a). Transmission electron microscopy revealed
the presence of normal cell walls with a thickness of 233
± 25 nm (Figure 2b–c), including a thin electron-dense
outer layer with delicate fibrillar structures clearly visible
(f in Figure 2c). A continuous cytoplasmatic membrane
(cm)lining a homogeneous and electron-dense cytoplasm
containing ribosomes, nucleus (n), and nucleoli (nu)
could also be observed (Figure 2b–c). Treatment of C. albi-
cans  with MIC50 of AZA (0.25 μg.ml-1) and EIL (1.00
μg.ml-1) induced significant morphological changes,
which ranged from discrete alterations to total destruction
of the fungal cells. A common alteration observed after
the treatment with AZA and EIL was a significant increase
in cell size, from 5 μm to 7 μm in diameter (Figure 2d, g,
j, and 2m). The number of altered cells was counted, and
the morphological alterations appeared in 34.79% and
55.17% of the cells after treatment with AZA and EIL,
respectively. Among the most frequently observed
ultrastructural alterations were: (i) presence of small buds
(asterisks in Figure 2d, g and 2j); (ii) irregular cell-wall
surfaces (arrows in Fig. 2D and 2E); (iii) loss of cell-wall
integrity, with an apparent shedding of cell components
(Fig. 2G–J, white and black arrows); and (iv) a two- to
three-fold increment of the cell wall thickness was
observed after treatment with AZA and EIL, respectively
(Figure 2f, i, l, and 2n). The cytoplasmic membrane of
treated cells also showed several changes, such as the pres-
ence of evaginations, discontinuity, detachment from the
cell wall (Figure 2e–f); budding of small vesicles that
could migrate through the periplasmatic region (Figure
2e–f, black arrowhead), accumulate in the cytoplasm (Fig-
Table 1: Susceptibility of ATCC strains to Δ24(25) sterol methyl transferase inhibitors, 20-piperidin-2-yl-5α-pregnan-3β, 20-diol (AZA) 
and 24 (R,S), 25-epiminolanosterol (EIL), and standard antifungals (FLC, ITC, and AMB) by the broth microdilution method.
Strains AZA EIL FLC ITC AMB
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
C. albicans ATCC 10231 > 16 > 16 1 > 16 1 > 128T 0.5 > 16T 0.12 0.25
C. parapsilosis ATCC 22019 0.25 4 2 4 2 4 0.03 0.06 0.03 0.06
C. tropicalis ATCC 13803 0.25 4 1 2 0.25 2 < 0.03 0.03 0.007 0.25
C. krusei ATCC 6258 0.05 1 > 16 > 16 32 64R 0.12 0.25 0.25 0.25
C. glabrata ATCC 2001 1 2 > 16 > 16 4 > 128T 0.12 4T 0.03 0.12
TTrailing Effect, RResistant
The values are expressed in μg.ml-1.BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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ure 2h–i, details in box), or remain close to the cell mem-
brane (Figure 2k–l, details in box). Vesicle sizes ranged
from 40–80 nm for AZA and 40–220 nm for EIL. Mito-
chondrial swelling and electron dense vacuoles accumula-
tion was also observed (m, Figure 2k–l). CNA cells treated
with MIC50 of 24-SMTI showed similar ultrastructural
changes (data not shown).
Presence of lipid bodies
Treatment with MIC50 of AZA and EIL induced an accu-
mulation of lipid bodies in the cytoplasm, which can be
characterised by the presence of small dots labelled with
Nile Red (Figure 3b–c), which were absent in the
untreated yeasts (Figure 3a). These lipid bodies seen by
fluorescence microscopy can be correlated with the small,
electron-dense vacuoles seen by transmission electron
microscopy (see above, ultrastructural effects).
Effect of 24-SMT inhibitors on the cell cycle
DAPI staining used to label the DNA revealed that the
treatment of C. albicans with AZA and EIL induced impor-
tant alterations in the cell cycle (Figure 4). To quantita-
tively assess these alterations, different stages of the
untreated yeasts were considered, such as: (I) cells con-
Table 2: Antifungal susceptibilities of 65 clinical isolates of Candida spp. to amphotericin B (AMB), fluconazole (FLC), and itraconazole 
(ITC) by the CLSI reference broth microdilution method.
Antifungal Species (no. of isolates) Concentration (μg.ml-1) Susceptibility no. isolates (%)
range of the MICs +MIC50
+MIC90 SS D D R
AMB All species (65) ≤ 0.007 – 1 0.06 0.12 65 (100) -
Candida albicans (21) ≤ 0.007 – 0.5 0.06 0.12 21 (100) -
Candida parapsilosis (19) 0.015 – 0.5 0.03 0.12 19 (100) -
Candida tropicalis (14) 0.015 – 1 0.06 0.25 14 (100) -
Candida glabrata (2) 0.015–0.5 0.12 0.25 2 (100) -
Candida krusei (1) 0.25 – 0.5 0.25 0.5 1 (100) -
Candida lusitaneae (1) 0.06 – 0.12 0.06 0.12 1 (100) -
Candida guilliermondii (3) 0.015 – 1 0.015 0.06 3 (100) -
Candida zeylanoides (1) 0.06 – 0.12 0.06 0.12 1 (100) -
Candida rugosa (1) 0.03 – 0.12 0.03 0.12 1 (100) -
Candida dubliniensis (1) 0.12 – 0.25 0.12 0.25 1 (100) -
Candida lipolytica (1) 0.12 – 0.25 0.12 0.25 1 (100) -
FLC All species (65) ≤ 0.25 – > 128* 0.5 1 60 (92.31) 2 (3.07) 3 (4.62)
Candida albicans (21) ≤ 0.25 – > 128* 0.25 4 21 (100)
Candida parapsilosis (19) ≤ 0.25 – > 128* 0.5 0.5 19 (100)
Candida tropicalis (14) ≤ 0.25 – > 128* 0.5 4.5 12 (85.71) 2 (14.29)
Candida glabrata (2) ≤ 0.25 – > 128* 4 64 2 (100)
Candida krusei (1) 16 – > 128 16 > 128 1 (100)
Candida lusitaneae (1) 0.5 – 1 0.5 1 1 (100)
Candida guilliermondii (3) 0.12 – 16 4 4 2 (66.67) 1 (33.33)
Candida zeylanoides (1) 4 – 16 4 16 1 (100)
Candida rugosa (1) 0.5 0.5 0.5 1 (100)
Candida dubliniensis (1) ≤ 0.25 – 0.5 ≤ 0.25 0.5 1 (100)
Candida lipolytica (1) 0.5 – 1 0.5 1 1 (100)
ITC All species (65) ≤ 0.03 – > 16** ≤ 0.03 0.12 49 (75.38) 10 (15.38) 6 (9.23)
Candida albicans (21) ≤ 0.03 – > 16** ≤ 0.03 ≤ 0.03 17 (80.95) 3 (14.28) 1 (4.76)
Candida parapsilosis (19) ≤ 0.03 – > 16** ≤ 0.03 ≤ 0.03 18 (94.74) 1 (5.26)
Candida tropicalis (14) ≤ 0.03 – > 16** ≤ 0.03 1.25 9 (64.28) 2 (14.28) 3 (21.43)
Candida glabrata (2) ≤ 0.03 – 4 0.5 2 1 (50) 1 (50)
Candida krusei (1) 0.12 – 2 0.5 2 1 (100)
Candida lusitaneae (1) ≤ 0.03 – 0.12 ≤ 0.03 0.12 1 (100)
Candida guilliermondii (3) 0.06 – 0.5 0.12 0.25 1 (33.33) 2 (66.66)
Candida zeylanoides (1) 0.06 – 0.12 0.06 0.12 1 (100)
Candida rugosa (1) ≤ 0.03 ≤ 0.03 ≤ 0.03 1 (100)
Candida dubliniensis (1) 0.06 – 0.12 0.06 0.12 1 (100)
Candida lipolytica (1) 0.25 – 0.5 0.25 0.5 1 (100)
-Not determinate; +MIC results are medians; *Trailing effect to FLC [C. albicans (9), C. tropicalis (4), C. parapsilosis (3) and one C. glabrata(1)]; 
**Trailing effect to ITC [C. albicans (6), C. tropicalis (4) and C. parapsilosis (1)].BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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taining one nucleus, (II) cells with a bud and one nucleus,
and (III) cells with a bud and two nuclei (one in each
cell). After treatment with the MIC50s of AZA and EIL, dif-
ferent alterations in the nucleus were observed, and these
were classified as: (A) cells with more than one nucleus,
(B) cells showing abnormal chromatin condensation, and
(C) cells without a nucleus. Counting the number of
abnormal cells revealed that approximately 66% of the
yeasts showed abnormal chromatin condensation,
whereas 6.6% of AZA-treated and 1.5% of EIL-treated cells
contained more than one nucleus, and approximately 6%
of the cells treated with both compounds had no nucleus
(Figure 4).
Cytotoxicity evaluation
Cytotoxicity of 24-SMTI was evaluated against mamma-
lian cells (Vero) using the sulforhodamine B viability
assay. For both AZA and EIL the CC50 was 40 μg.ml-1,
which corresponds to a mean selectivity index of 80 for
AZA and 20 for EIL.
Discussion
Although C. albicans is the predominant species in candi-
diasis, CNA species have increased in frequency in recent
years. The reasons for the emergence of CNA species are
not fully understood, but some medical conditions may
frequently run the risk of developing candidaemia due to
the CNA species: C. parapsilopsis has been associated with
vascular catheters and parenteral nutrition; C. tropicalis
with cancer and neutropenia; and C. krusei and C. glabrata
with previous treatments with FLC and ITC [2].
Previous studies have described a high susceptibility of C.
albicans isolates to azoles and AMB, whereas CNA isolates
are usually less susceptible and may be intrinsically resist-
ant to FLC and ITC [2,15-17]. As reported by other inves-
tigators [2,18,19], none of our Candida isolates showed
MIC ≥ 2 μg.ml-1 for AMB. MIC values found for ITC and
FLU were similar to those previously reported by different
groups [2,15-17]. However, in the present study, FLC-
resistant Candida strains were only observed among CNA
species (6.8% of the isolates). However, ITC-resistance
was found in C. albicans (1.5%) and CNA isolates (7.7%).
The observation of a high positive correlation between
MIC values of FLC and ITC (r = 0.79 for MIC50 and r = 0.71
for MIC90), in this study, suggests that cross-resistance
may be occurring. However, no correlation was observed
Table 3: Antifungal activity of 20-piperidin-2-yl-5α-pregnan-3β,20-diol (AZA) and 24 (R,S),25-epiminolanosterol (EIL), Δ24(25)-sterol 
methyl transferase inhibitors, against 65 clinical isolates of Candida spp. by the CLSI reference broth microdilution method.
Drugs Species (no. of isolates) Concentration (μg.ml-1)
range of the MICs +MIC50
+MIC90
AZA All species (65) ≤ 0.03 – > 16 0.5 2
Candida albicans (21) 0.06 – > 16 0.5 8
Candida parapsilosis (19) 0.06 – > 16 0.12 0.5
Candida tropicalis (14) 0.06 – > 16 0.62 8
Candida glabrata (2) 0.12 – > 16 1 2
Candida krusei (1) 16 – > 16 16 > 16
Candida lusitaneae (1) 0.06 – 0.5 0.06 0.5
Candida guilliermondii (3) ≤ 0.03 – 0.5 0.06 0.25
Candida zeylanoides (1) ≤ 0.03 ≤ 0.03 ≤ 0.03
Candida rugosa (1) 0.25 – 1 0.25 1
Candida dubliniensis (1) 0.5 – 2 0.5 2
Candida lipolytica (1) > 16 > 16 > 16
EIL All species (65) ≤ 0.03 – > 16 2 2
Candida albicans (21) 0.5 – 8 2 2
Candida parapsilosis (19) 0.5 – 8 1 2
Candida tropicalis (14) 1 – 8 1 2
Candida glabrata (2) 0.5 – 4 1 2
Candida krusei (1) 8 8 8
Candida lusitaneae (1) 0.5 – 2 0.5 2
Candida guilliermondii (3) 1 – 4 1 4
Candida zeylanoides (1) 1 – 2 1 2
Candida rugosa (1) 1 – 2 1 2
Candida dubliniensis (1) 2 – 8 2 8
Candida lipolytica (1) ≤ 0.03 ≤ 0.03 ≤ 0.03
+MIC results are medians.BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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between MIC values of the azoles and 24-SMTI, indicating
lack of possible cross-resistance.
The general finding for our Candida spp. isolates was that
they were mostly susceptible to AZA and EIL, because the
MIC50s were lower than 2 μg.ml-1 for 73% and 88% of the
isolates after treatment with AZA and EIL, respectively.
Interestingly, some FLC- and ITC-resistant strains were
susceptible to 24-SMTI. However, residual growth of Can-
dida after treatment with AZA was similar to that observed
for FLC and ITC. No residual growth was observed after
treatment with EIL. The fungicidal action of 24-SMTI was
more prominent against CNA species than against C. albi-
cans isolates. A concentration of 4.0 μg.ml-1 of 24-SMTI
was enough to kill 100% of C. lusitanae, C. zeylanoides, and
C. rugosa, and 50% of C. glabrata. In contrast, this same
concentration killed only 4.7% and 9.5% of C. albicans
isolates, considering AZA and EIL respectively.
Previous studies have shown that azasterol derivatives
have antifungal activity against a variety of species [7]. 15-
azasterol, in concentrations ranging from 0.01 μg.ml-1 to
4.08 μg.ml-1, inhibits the growth of Saccharomyces cerevisae
and  C. albicans, with a concomitant accumulation of
sterol intermediate molecules [20,21]. The range of MIC
and MFC values for 15-azasterol analogues against these
fungal species varied from 0.8 to 3.1 μg.ml-1 and 3.1 to 6.3
μg.ml-1, respectively [7] and are similar to the values
obtained in the present study.
Other azasterol derivatives have been shown to inhibit S.
cerevisae 24-SMT, leading to the accumulation of zymos-
terol [22]. Recent work demonstrated that AZA displays
antifungal activity against Paracoccidioides brasiliensis [14]
and  Pneumocystis carinii [13]. Concentrations of 5 μM
(2.05 μg.ml-1) inhibited 100% of the growth in P. brasil-
iensis, and the treatment of P. carinii with the IC50 of 0.3
μM (0.12 μg.ml-1) led to growth arrest and accumulation
of 24-desakyl sterols, indicating an inhibition of 24-SMT
[13]. In addition, previous studies have also shown an
anti-protozoan activity of AZA and EIL on T. cruzi epimas-
tigotes and intracellular amastigotes [10], L. amazonensis
promastigotes and intracellular amastigotes [11,12], Tox-
oplasma gondii [23], and Giardia lamblia [24], with MICs in
the low μM to sub-μM range. For protozoans, EIL was
reported to be more active than AZA. In contrast, we
found in this study that AZA was more active than EIL
against Candida spp. isolates.
Treatment of C. albicans yeasts with AZA and EIL caused
dramatic changes in their cellular and sub-cellular struc-
ture. The main alterations included changes in the cell
wall shape and thickness, a pronounced disconnection
between the cell wall and cytoplasm, with the presence of
an electron-lucent zone between them, cell collapse and
release of cellular content, mitochondrial swelling, and
abnormalities in the nuclear structure. These findings are
similar to those previously reported after treatment of
Candida spp. with different azoles [25-28]. Borges and co-
Table 4: Cumulative MFC profile of 65 clinical isolates of Candida spp. treated with 20-piperidin-2-yl-5α-pregnan-3β,20-diol (AZA) and 
24(R,S),25-epiminolanosterol (EIL).
Cumulative MFC* (μg.ml-1)
Species (no. isolates) Drugs 0.03 1 2 4 8 16 > 16
All species (65) AZA 1.52 3.04 12.16 16.72 34.96 44.08 100
EIL 6.08 15.20 30.40 51.68 100
Candida albicans (21) AZA 4.76 4.76 9.52 9.52 100
EIL 9.52 28.57 61.98 100
Candida parapsilosis (19) AZA 5.26 26.31 36.87 68.42 68.42 100
EIL 10.52 15.79 26.31 63.15 100
Candida tropicalis (14) AZA 35.71 64.28 100
EIL 7.17 7.17 35.71 42.87 100
Candida glabrata (2) AZA 50 50 50 50 100
E I L 5 05 05 0 1 0 0
Candida krusei (1) AZA 100
EIL 100
Candida lusitaneae (1) AZA 100
EIL 100 100 100 100
Candida guilliermondii (3) AZA 100
EIL 100
Candida zeylanoides (1) AZA 100 100 100 100 100 100 100
EIL 100 100 100 100 100
Candida rugosa (1) AZA 100 100 100 100
EIL 100
* data is expressed in percentual of isolates.BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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Scanning electron microscopy (left column) and transmission electron microscopy (two right columns) micrographs of C. albi- cans (isolate 77) untreated (Fig. A-C) and treated with MIC50 of AZA (0.25 μg.ml-1) (Fig. D-F) and EIL (1 μg.ml-1) (Fig. G-L) for  48 h at 35°C Figure 2
Scanning electron microscopy (left column) and transmission electron microscopy (two right columns) micro-
graphs of C. albicans (isolate 77) untreated (Fig. A-C) and treated with MIC50 of AZA (0.25 μg.ml-1) (Fig. D-F) 
and EIL (1 μg.ml-1) (Fig. G-L) for 48 h at 35°C. Control cells have a normal ultrastructure, with nucleus (n), nucleoli (nu), 
continuous cytoplasmatic membrane (cm), compact cell wall (cw) with fibrillar structures (f), and several ribosomes in the 
cytoplasm (Fig. A-C). Treated cells show ultrastructural alterations, such as: presence of small buds (asterisks in Fig. 2D, G and 
J); cell-wall disruption (black and white arrows in Fig. D-J), and increased thickness (cw in Fig. F, I and L); budding of small vesi-
cles coming from the intracellular membranes (arrowhead in Fig. F); accumulation of small vesicles in the periplasmatic region 
(inset in Fig. F), in cytoplasm (inset in Fig. I), and in close association with the cytoplasmatic membrane (inset in Fig. L); accumu-
lation of electron-dense vacuoles (v in Fig. K) and mitochondrial swelling (m in Fig. K). The effect of 24-SMT inhibitors on cell 
size and on cell wall thickness was measured and statistically analysed (Fig. M and N, respectively). Bars in A, D, G, and J = 5 
μm; B, E, H, and K = 1 μm; C, F, I, and L = 0.2 μm. * p < 0.01; **p < 0.001; ***p < 0.0001.BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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workers [27] reported that exposure of Candida albicans to
ITC leads to primary alterations at the cell periphery and
the appearance of vacuoles in the cytoplasm, which may
be lipid inclusions. These changes were usually accompa-
nied by an increase in the cell volume and impaired cell
division. In addition, studies by Hazen and co-workers
[28] revealed that Candida treated with FLC shows a dis-
tinct retraction of the membrane from the cell wall. On
the other hand, C. albicans treated with low concentra-
tions of AMB shows chromatin condensation and margin-
ation, separation of the nuclear envelope, and nuclear
fragmentation [29]. High concentrations of AMB induce
cellular changes characteristic of necrosis, showing many
large vacuoles [29]. Additionally, Bahmed and co-workers
[30] demonstrated an increase in cell wall thickness of
Candida yeasts, which may be related to alterations in the
cell wall composition induced by the treatment with
AMB.
In addition, similar to our findings, the appearance of
multivesicular bodies and myelin-like structures were
reported after treatment of Leishmania [11,12] and T. cruzi
[31] with AZA and EIL.
Staining with Nile Red revealed the presence of lipid accu-
mulation in the cytoplasm after treatment with 24-SMTI,
confirming that these compounds induce a perturbation
in lipid biosynthesis. Similar observations have recently
been made as the result of treatment of Leishmania amazo-
nensis with 24-SMTI, which induced several abnormalities
in the lipid content, with the accumulation of steroid
intermediate molecules [12].
In addition, staining of DNA with DAPI indicates a pro-
found alteration in the cell cycle after treatment with AZA
and EIL. Candida  yeasts produced unfertile buds that
remained closely associated with the mother cell, and
appeared with or without various nuclei. The nucleus may
also have an altered shape and/or with abnormal chroma-
tin condensation that might be associated with apoptosis
cell death, as previously described after treatment of C.
albicans with AMB [29]; and also after treatment of Tritri-
chomonas foetus with hydrogen peroxide [32]. The pres-
ence of many cells with more than one nucleus may also
indicate that ergosterol biosynthesis inhibitors are inter-
fering with cytokinesis. In fact, it was previously found
that ergosterol levels modulate the activity of protein
kinases such as pp60v-src and also the levels of cAMP,
both of which are directly related to the control of the cell
cycle [33,34].
In addition, some studies have shown that drugs such as
griseofulvin and nocodazole, which interfere with the
assembly of cytoskeleton components, induce alterations
in the cell cycle and apoptosis cell death [35-37]. Thus,
there are two possible explanations for the alterations in
the cell cycle: (a) the depletion of ergosterol and other lip-
ids, which are essential for the maintenance of the cyto-
plasmatic membrane structure and are also important key
regulators of the cell cycle; and/or (b) alterations in the
cytoskeleton structure, which can affect the cytokinesis
process. The results obtained here suggest that AZA and
EIL are probably interfering with sterol biosynthesis in
Candida spp., as previously described for C. albicans [20],
P. carinii [13], T. cruzi [3], and L. amazonensis [12]. On the
other hand, we cannot exclude the possibility that these
compounds may be acting in other pathways, inducing
some secondary effects that could be related to the accu-
mulation of other lipids or, as demonstrated in Crithidia
deanei, that AZA can interfere with phospholipid biosyn-
thesis [38]. Further studies are necessary to characterise
the correlation between the depletion of ergosterol and
the cell cycle in C. albicans.
Differential Interference Contrast (DIC) microscopy (left)  and fluorescence microscopy with Nile Red (right) of C. albi- cans (isolate 77) control (A), treated with MIC50 of AZA  (0.25 μg.ml-1) (B) and EIL (1 μg.ml-1) (C) for 48 h at 35°C,  showing the presence of lipid droplets Figure 3
Differential Interference Contrast (DIC) microscopy 
(left) and fluorescence microscopy with Nile Red 
(right) of C. albicans (isolate 77) control (A), treated 
with MIC50 of AZA (0.25 μg.ml-1) (B) and EIL (1 
μg.ml-1) (C) for 48 h at 35°C, showing the presence of 
lipid droplets. Bars = 5 μm.BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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Conclusion
The results presented herein demonstrate the potential
usefulness of the 24-SMT inhibitors AZA and EIL as anti-
fungal agents, including azole-resistant Candida strains.
The specific in vitro and in vivo antifungal and antiproto-
zoal activity of azasterols has been known for years, and
in most cases has been linked to their specific inhibition
of 24-SMT, an enzyme absent in mammals [10-14,39].
However, other studies have found that these compounds
are also active against parasitic protozoa that lack endog-
enous sterol biosynthesis, such as T. gondii [23,40] and
Trypanosoma brucei [41], indicating that they may have
other biochemical targets. Taken together, these results
indicate azasterols as useful leads for novel antifungal
agents, but optimisation of their selectivity, ADME, PK,
and toxicological properties is required for their further
advancement as drug candidates.
Methods
Microorganisms
Antifungal assays were performed against 70 yeasts of the
genus Candida. Five standard strains from the American
Type Culture Collection (ATCC): Candida albicans ATCC
10231, Candida krusei ATCC 6258, Candida glabrata ATCC
2001, Candida parapsilosis ATCC 22019, and Candida trop-
icalis ATCC 13803; and 65 clinical isolates: Candida albi-
cans (21), Candida parapsilosis (19), Candida tropicalis (14),
Candida guilliermondii (3), Candida glabrata (2), Candida
krusei (1), Candida lusitaneae (1),Candida zeylanoides (1),
Candida rugosa (1),Candida dubliniensis (1), and Candida
lipolytica (1) were used. The clinical isolates came from
bloodstream (35%), urine (26%), and other clinical
material (39%), and were isolated from 2002 to 2006 at
the Microbiology/Mycology Laboratory of Hemorio, Rio
de Janeiro, Brazil. Species identification was performed by
micromorphology analysis and Vitek Systems (Biomer-
ieux Inc., France). The isolates were maintained in Sab-
ouraud dextrose agar plates at 4°C, and subcultures were
used in each experiment.
Drugs
20-piperidin-2-yl-5α-pregnan-3β, 20-diol (22,26-azas-
terol or AZA) (Fig. 1) and 24(R,S),25-epiminolanosterol
(EIL) (Fig. 1), Δ24(25)-sterol methyltransferase inhibitors,
were synthesised, purified, and characterised as described
by Urbina et al. [10]. Fluconazole (FLC) (Pfizer, São
Paulo, Brazil), Itraconazole (ITC), and Amphotericin B
(AMB) (both from Sigma Chemical Co., Missouri, USA)
were used as reference antifungals. Drugs were diluted in
dimethyl sulfoxide (DMSO) to obtain 100-times stock
solutions and maintained at -70°C.
Antifungal susceptibility test
The minimal inhibitory concentration (MIC) of each drug
was obtained using the broth microdilution technique as
described in document M27-A3 of the Clinical and Labo-
ratory Standards Institute – CLSI [42]. Briefly, serial two-
fold dilutions of the drugs were performed in RPMI 1640
medium (Sigma Chemical Co., Missouri, USA), buffered
with MOPS 0.16 M, pH 7.0, into 96-well microtitre trays
to obtain concentration ranges of 0.03–16 μg.ml-1 (AZA,
EIL, and ITC), 0.25–128 μg.ml-1  (FLC) and 0.007–4
μg.ml-1 (AMB). Next, the yeast inoculum was adjusted to
1–5 × 106CFU.ml-1. Dilutions of 1:50 and 1:20 in RPMI
1640 medium were performed to obtain 1–5 × 103
CFU.ml-1, and an aliquot was dispensed into each well.
The microtitre trays were incubated at 35°C, for 48 h.
MIC50 and MIC90 values (MICs that inhibit 50% and 90%
of the yeast growth in relating to control, respectively)
were determined using a spectrophotometer at 492 nm.
MIC50 and MIC90 median values for test and standard
drugs were also determined. Clinical isolates were classi-
fied according to their MIC in three different categories:
Differential Interference Contrast (DIC) microscopy (left)  and fluorescence microscopy with DAPI (right) of C. albicans  (isolate 77) control and treated with MIC50 of AZA and EIL,  showing alterations in the cell cycle such as the presence of  cells with multiple nuclei (arrows in Fig. D and G), abnormal  chromatin condensation (arrowheads in Fig. E and H), and  cells without a nucleus (asterisk in Fig. F and I) Figure 4
Differential Interference Contrast (DIC) microscopy 
(left) and fluorescence microscopy with DAPI (right) 
of C. albicans (isolate 77) control and treated with 
MIC50 of AZA and EIL, showing alterations in the cell 
cycle such as the presence of cells with multiple 
nuclei (arrows in Fig. D and G), abnormal chromatin 
condensation (arrowheads in Fig. E and H), and cells 
without a nucleus (asterisk in Fig. F and I). A-C: con-
trol cells in different stages of the cell cycle; D-F: 0.25 μg.ml-
1 AZA; G-I: 1 μg.ml-1 EIL; J: Percentage of C. albicans cells, 
untreated and treated with 24-SMT inhibitors, showing dif-
ferent cell cycle stages: (I) cells with no bud and one nucleus, 
(II) cells with a bud and one nucleus, and (III) cells with a bud 
and two nuclei (one in each cell); and alterations of cell 
cycles: (A) cells with more than one nucleus, (B) cells show-
ing abnormal chromatin condensation, and (C) cells without 
a nucleus. Bar = 5 μm.BMC Microbiology 2009, 9:74 http://www.biomedcentral.com/1471-2180/9/74
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susceptible (S), susceptible dose-dependent (SDD), or
resistant (R). Interpretative breakpoints proposed by the
CLSI [42] for FLC and ITC were used, and concentrations
above 1 μg.ml-1 were considered resistant for AMB [43].
Trailing effect for FLC and ITC was detected at visual read-
ing after 24 h of incubation.
The minimum fungicidal concentration (MFC) was deter-
mined after 48 h of treatment with the inhibitory concen-
trations used in the susceptibility test. An aliquot of each
Candida isolate was transferred onto Sabouraud dextrose
agar plates without the presence of drugs. The plates were
incubated at 35°C for 48 h, and the minimum fungicidal
concentration (MFC) was determined. MFC means the
lowest concentration that showed no fungal growth [44].
Fluorescence microscopy
C. albicans (isolate 77) was treated with MIC50 of AZA and
EIL at 35°C for 48 h. Yeasts were washed in PBS, pH 7.2
and fixed with 4% paraformaldehyde in PBS for 30 min.
Next, the yeasts were adhered to coverslips with poly-L-
lysine and incubated with 5 μg.ml-1 Nile Red (Fluka, USA)
for 30 min to label the lipid bodies and 1 μg.ml-1 DAPI
(Sigma Chemical Co., Missouri, USA) for 10 min to label
the DNA. Coverslips were mounted in n-propylgallate
solution and observed in a Zeiss Axioplan epifluorescence
microscope equipped with rhodamine (Nile Red fluores-
cence) and DAPI filters, and the images were recorded
with a C5810 Hamamatsu camera. The number of altered
Candida was determined after the counting of at least 300
yeast cells. Cell size was measured by means of the SemA-
fore 5.0 software (Jeol, Japan).
Transmission electron microscopy
C. albicans (isolate 77) was treated with MIC50 of AZA and
EIL at 35°C, for 48 h. Yeasts were washed in PBS, pH 7.2
and fixed in a solution of 2.5% glutaraldehyde and 4%
freshly prepared formaldehyde in 0.1 M cacodylate buffer,
pH 7.2, for 2 h at room temperature. After fixation, yeasts
were post-fixed for 2 h in 1% osmium tetroxide contain-
ing 1.25% potassium ferrocyanide and 5 mM CaCl2 in
cacodylate buffer, pH 7.2, washed in the same buffer,
dehydrated in ethanol, and embedded in Spurr. Ultrathin
sections were stained with uranyl acetate and lead citrate,
and images were obtained in a Zeiss 900 electron micro-
scope equipped with a CCD Camera (Mega view III
model, Soft Image System, Germany). Images were proc-
essed with iTEM software (Soft Image System, Germany).
Cell wall thicknesses and vesicles of untreated and treated
yeasts were measured by means of the SemAfore 5.0 soft-
ware (Jeol, Japan).
Scanning electron microscopy
C. albicans (isolate 77) treated with MIC50 of AZA and EIL
at 35°C for 48 h, was fixed as described above for trans-
mission electron microscopy, and subsequently dehy-
drated in ethanol, critical-point dried in CO2, coated with
gold, and observed in a JEOL JSM-5310 scanning electron
microscope.
Cytotoxicity tests in mammalian cells
Green monkey kidney (Vero) cells were maintained in
Dulbecco's modified Eagle's medium (DMEM, Gibco Inv-
itrogen Corporation, New York, USA) supplemented with
2 mM L-glutamine, 10% heat-inactivated fetal bovine
serum (FBS), and 50 μg.ml-1 gentamicin at 37°C in a 5%
CO2/air mixture. In 96-well microtitre trays, 2.5 × 104
cells/well were dispensed and incubated for 24 h. Monol-
ayers of Vero cells were treated with different concentra-
tions of 24-SMTI for 48 h at 37°C in 5% CO2 and fixed in
10% trichloroacetic acid for 1 h at 4°C, stained with sul-
forhodamine B for 30 min at 4°C, and the optical densi-
ties were obtained in a spectrophotometer at 530 nm [45].
The 50% cytotoxic concentration (CC50) and the selectiv-
ity index (SI = CC50/MIC50) were calculated.
Statistical analysis
Statistical analyses were performed with the Prism 5.0
software, and p < 0.05 was considered as significant. Dif-
ferences in the cell size and cell-wall thickness of
untreated and treated Candida spp. were analysed by one-
way ANOVA (Dunnett test), and MIC values were ana-
lysed by linear regression test.
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